The Antipsychotics Market Insight and Analysis 2008

Chapter 2 Introduction
2.1 Antipsychotics Overview
2.2 Schizophrenia
2.2.1 Classic Symptoms of Schizophrenia
2.2.2 Diagnosis of Schizophrenia
2.2.3 Epidemiology of Schizophrenia
2.2.4 Causes and Physiological Characteristics of Schizophrenia
2.3 Bipolar Disorder
2.3.1 Symptoms of Bipolar Disorder
2.3.2 Causes of Bipolar Disorder
2.3.3 Diagnosis of Bipolar Disorder
2.4 Antipsychotic Drugs
2.5 Mechanisms of the Newer Therapeutic Agents - The Atypical Antipsychotics
2.6 An Overview of How the Typical Antipsychotic Drugs Differ from the Atypical Antipsychotics
2.7 Off-Label Prescription Extending Approved Indications for Atypical Antipsychotic Drugs
2.8 The Prospects for Patients

Chapter 3 The World Antipsychotic Drug Market, 2006-2012
3.1 The Antipsychotic Market Contains Four Major Blockbusters and Set For a Fifth
3.2 Despite Five Major Blockbuster Drugs, the Antipsychotic Market Will Decline in Growth
3.3 Zyprexa Will Show Negative Growth Due to Weight Gain Problems and Patent Expiration
3.4 Risperdal Faces Generic Threat
3.5 Seroquel Shows Strong Growth – But Will it Last?
3.6 Abilify Will Remain a Strong Contender
3.7 Zeldox/Geodon Set to Reach Blockbuster Status
3.8 Can Leponex/Clozaril “Re-Invent” itself to Offset Decline?
3.9 Zyprexa Will Lose Market Leadership to Seroquel
3.10 Eli Lilly Currently Leads the Antipsychotic Drug Market
3.11 Market Expansion
3.12 Comparative Studies on Antipsychotic Drugs – A Blessing or a Curse for the Market
Leaders?
3.13 The Antipsychotic Market 2006-2012: Conclusions

Chapter 4 An Analysis of Factors that Influence the Antipsychotic Market
4.1 SWOT Analysis of the Antipsychotic Market
4.2 What Are the Main Drivers, Strengths and Opportunities in the Antipsychotic Market?
4.3 The Atypical Antipsychotics Constitute a Large Market
4.4 There is Scope for Greater Penetration into Related Markets
4.5 Advances in Technology Likely to Bring Benefits to the Market
4.6 Comparative Studies - a Two Edged Sword
4.7 The Principal Restraints in the Antipsychotic Market
4.8 Patent Expiry Among the Leading Antipsychotic Drugs – An Increasing Threat
4.9 Risk of Diabetes and Other Serious Side Effects with the Atypical Antipsychotic Drugs
4.10 Breaking the Prescribing Habit for Off-Label Use of Antipsychotics
4.11 Concerns Over the High Price of the Treatments - Who Yields the Power?
4.12 A Discussion of Generic Drugs in This Market - How Great is Their Threat?

Chapter 5 A Geographical Breakdown of the World Antipsychotics Market & Major Companies Involved
5.1 Antipsychotics - A World Market Led by US Sales
5.2 The US and Europe are the Most Important Markets for Antipsychotic Drugs

Chapter 6 An Analysis of Unmet Needs in the Antipsychotics Market
6.1 Analysing Efficacy, Safety and Tolerability in the Antipsychotics Market via Perceptual Mapping
6.2 How Much Scope is There to Improve Efficacy in Antipsychotic Drugs?
6.3 How Much Scope is There to Improve Safety and Tolerability in Antipsychotic Drugs?
6.4 Pricing of the Atypical Antipsychotics - Close Scrutiny by Medical Authorities and Concern Amongst Patients' Groups
6.5 Screening and Diagnosis by Healthcare Services is a Necessary Pre-requisite for Market Growth
6.6 Direct-to-Consumer Advertising - An Opportunity to Educate Consumers but also a Source of Controversy

Chapter 7 Pipeline Drugs for Antipsychotics
7.1 Agents in Phase II of Clinical Development
7.1.1 GSK’s 742457 and 773812
7.1.2 GSK’s Talnetant
7.1.3 BL-1020 from Bioline Rx
7.1.4 Memory’s MEM 3454 and MEM 1003
7.1.5 Richter's RGH-188
7.1.6 Eli Lilly’s LY2140023
7.1.7 All Agents in Phase II development
7.2 Agents in Phase III of Clinical Development
7.2.1 ACADIA’s Pimavanserin
7.2.2 Novartis’s Licarbazepine
7.3 Agents in Pre-Registration
7.3.1 Iloperidone
7.3.2 Asenapine (ORG 5222)
7.3.3 Bifeprunox
7.3.4 Blonanserin
7.4 Summary of All Pipeline Agents from Phase II and above
7.5 An Overall Assessment of Pipeline Developments for the Antipsychotics Market

Chapter 8 Conclusions: the Antipsychotics Market Will Face Decreasing Growth

List of Tables

Table 1.1 Leading Antipsychotic Drugs, 2006
Table 2.1 First Generation Antipsychotic Drugs for Treating Schizophrenia (the Typical Antipsychotics)
Table 2.2 Mild and Serious Side Effects of First Generation Antipyshcotics
Table 2.3 Second Generation Antipsychotic Drugs for Treating Schizophrenia (the Atypical Antipsychotics)
Table 2.4 Mild and Serious Side Effects of Second Generation Antipyshcotics
Table 2.5 Top Antipsychotic Product Revenues ($m) and Market Share (%), 2006
Table 3.1 The Leading Drugs for Treating Schizophrenia: Indications and Marketed Country/Region, 2007
Table 3.2 World Revenues ($m) for the Leading Antipsychotic Drugs 2006-2012
Table 3.3 World Revenues for Antipsychotic Drugs 2006 and 2012 Compared
Table 3.4 The Global Market Share (%) by Revenue for Antipsychotic Drugs, 2006, 2009 and 2012
Table 3.5 Top 10 Leading Companies in the Antipsychotic Drug Market, Revenue and Market Share, 2006
Table 3.6 The Relative Strengths and Weaknesses of the Leading Schizophrenia Drugs with a Prediction of their Future Sales Potential
Table 4.1 A SWOT Chart for the Antipsychotic Market
Table 4.2 A Comparison of the Leading Antipsychotic Drugs' Side Effect Profiles
Table 5.1 A Breakdown of the Antipsychotics Market by Country in 2006
Table 5.2 Regional Breakdown of Antipsychotic Sales ($m) and Market Share (%), 2006
Table 6.1 Efficacy and Side Effect Profiles of the Leading Antipsychotic Drugs
Table 7.1 Antipsychotic Drugs in Phase II Clinical Trials in 2007
Table 7.2 Summary of All Pipeline Products Phase II and Above, 2007
Table 8.1 The Leading Antipsychotic Drugs, Revenue ($m) and Market Share (%), 2006

List of Figures

Figure 3.1 Total World Revenues ($m) for the Antipsychotic Market 2006-2012
Figure 3.2 World Antipsychotic Market Revenues ($m) by Drug, 2006-2012
Figure 3.3 World Revenue Forecast ($m) for Zyprexa 2006-2012
Figure 3.4 World Revenue Forecast ($m) for Risperdal 2006-2012
Figure 3.5 World Revenue Forecast ($m) for Seroquel 2006-2012
Figure 3.6 World Revenue Forecast ($m) for Abilify 2006-2012
Figure 3.7 World Revenue Forecast ($m) for Zeldox/Geodon 2006-2012
Figure 3.8 World Revenue Forecast ($m) for Leponex/Clozaril 2006-2012
Figure 3.9 Market Share (%) by Revenue of Antipsychotic Drugs, 2006
Figure 3.10 Market Share (%) by Revenue of Antipsychotic Drugs, 2009
Figure 3.11 Market Share (%) by Revenue of Antipsychotic Drugs, 2012
Figure 3.12 Top 10 Leading Companies in the Antipsychotic Drug Market ($m), 2006
Figure 3.13 Leading Companies in the Antipsychotic Drug Market, Market Share (%), 2006
Figure 5.1 Market Share (%) for Antipsychotics by Country, 2006
Figure 5.2 Revenues ($m) for Antipsychotic Market by Country, 2006
Figure 5.3 Regional Breakdown of the Antipsychotics Market ($m), 2006
Figure 5.4 Regional Breakdowns of Antipsychotics, Market Share (%), 2006
Figure 6.1 A Comparison of the Atypical Antipsychotics via Perceptual Mapping
Figure 8.1 World Antipsychotics Market Revenue Forecast ($m) by Drug, 2006-2012